• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed

    2/12/21 10:16:25 AM ET
    $EKSO
    Industrial Machinery/Components
    Industrials
    Get the next $EKSO alert in real time by email
    SC 13G 1 ea135263-sc13gazimut_ekso.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)


    (Amendment No. __)*

     

    EKSO BIONICS HOLDINGS, INC.

    (Name of Issuer)

     

    Common Stock, $0.001 par value per share

    (Title of Class of Securities)

     

    282644301

    (CUSIP Number)

     

    September 15, 2020

    (Date of event which requires filing of this statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    þ Rule 13d-1(b)

     

    ☐ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     2 of 9

     

    1

    NAMES OF REPORTING PERSONS

     
    AZ Fund 1 AZ Allocation –Trend

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY

     

    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5 SOLE VOTING POWER

    0 Shares
    6 SHARED VOTING POWER

    423,000 Shares
    7 SOLE DISPOSITIVE POWER

    0 Shares
    8 SHARED DISPOSITIVE POWER

    423,000 Shares

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    423,000 Shares
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.086%

    12 TYPE OF REPORTING PERSON

    CO

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     3 of 9

     

    1

    NAMES OF REPORTING PERSONS

     

    Azimut Investments S.A.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ☒

    (b) ☐

    3

    SEC USE ONLY

     

    4 CITIZENSHIP OR PLACE OF ORGANIZATION

    Luxembourg

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON WITH

    5 SOLE VOTING POWER

    0 Shares
    6 SHARED VOTING POWER

    423,000 Shares
    7 SOLE DISPOSITIVE POWER

    0 Shares
    8 SHARED DISPOSITIVE POWER

    423,000 Shares

    9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    423,000 Shares
    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.086%

    12 TYPE OF REPORTING PERSON

    CO

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     4 of 9

     

    Item 1(a). Name of Issuer:
       
      EKSO Bionics Holdings, Inc.
       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
     

    1414 Harbour Way South, Suite 1201

    Richmond, CA 94804

    United States

       
    Item 2(a). Name of Person Filing:
       
     

    This Statement is filed by each of the entity and person listed below, referred to herein as the “Reporting Person”:

     

     

    (i) AZ Fund 1 - AZ Allocation - Trend is a Sub-fund of AZ Fund 1, an umbrella fund established under Luxembourg law, pursuant to Part I of the Law of 17 December 2010 relating to undertakings for collective investment, created in accordance with fund management regulations (the “Management Regulations”) approved on 4 February 2000 by the Board of Directors of AZ Fund Management S.A. (currently “Azimut Investments S.A.”) (the “Management Company”) and published in the Memorial Compendium of Companies and Associations (the “Memorial”) on 13 March 2000 after having been filed with the Registrar of the District Court of Luxembourg on 28 February 2000. The Management Regulations were amended on 27 April 2001, 4 December 2002, 13 February 2006, 29 May 2006, 18 July 2006, 11 December 2006, 25 January 2008, 29 February 2008, 10 September 2008, 19 January 2009, 27 April 2009, 3 February 2010, 1 March 2010, 20 August 2012, 18 November 2014 and 4 January 2021. The latest amendments were filed with the Business Register on 14 January 2021. As an umbrella fund, the Fund has no legal personality. Its assets belong to its investors (joint tenancy) and are separate from those of the Management Company and any other fund managed.

     

    Azimut Investments S.A. is a Luxembourg corporation that manages the affairs of AZ Fund 1 - AZ Allocation - Trend. Claudio Basso is the Chief Investment Officer of the Management Company. The Management Company and Claudio Basso may be deemed to share voting and dispositive control over the shares held by AZ Fund 1 AZ Allocation – Trend.

     

    (ii) The Management Company manages the Sub-fund identified in (i) above and may be deemed to share voting and dispositive control over the shares held by the Sub-fund.

     

    Item 2(b). Address of Principal Business Office or, if None, Residence:
       
     

    The address of the principal business office of the Reporting Person is:

     

    c/o Azimut Investments S.A.

    35, Avenue Monterey

    L-2163 Luxembourg

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     5 of 9

     

    Item 2(c). Citizenship:
       
     

    AZ Fund 1 AZ Allocation - Trend – Luxembourg

    Azimut Investments S.A. – Luxembourg

       
    Item 2(d). Title of Class of Securities:
       
      Common Stock, par value $0.001 per share
       
    Item 2(e). CUSIP Number:
       
      282644301
       
    Item 3. If This Statement is Filed Pursuant to Rules 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

        (a) ☐ Broker or dealer registered under Section 15 of the Exchange Act;
        (b) ☐ Bank as defined in Section 3(a)(6) of the Exchange Act;
        (c) ☐ Insurance company as defined in Section 3(a)(19) of the Exchange Act;
        (d) ☐ Investment company registered under Section 8 of the Investment Company Act;
        (e) ☐ An investment adviser in accordance with Rule 13d-1(b)(ii)(E);
        (f) ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
        (g) ☐ A parent holding company or control person in accordance with Rule 13d-1(b)(ii)(G);
        (h) ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
        (i) ☐ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
        (j) þ A non-U.S. institution, in accordance with Rule 13d-1(b)(1)(ii)(J);
        (k) ☐ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     6 of 9

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: Foreign mutual funds.

     

    Item 4. Ownership.
       
      AZ Fund 1 AZ Allocation - Trend
       
      (a) Amount Beneficially Owned: 423,000 Common Stock shares.
       
      (b) Percent of Class: 5.086% based on 8,316,308 Common Shares outstanding, as reported on Form 10-Q, Quarterly Report Pursuant To Section 13 or 15(d) of The Securities Exchange Act of 1934, filed on October 29, 2020.
       
     

    (c) Number of shares as to which the person has

     

    (i)Sole power to vote or direct the vote: 0
       
    (ii)Shared power to vote or direct the vote: 423,000
       
    (iii)Sole power to dispose or direct the disposition: 0
       
    (iv)Shared power to dispose or direct the disposition: 423,000

     

      Azimut Investments S.A.
       
      (a) Amount Beneficially Owned: 423,000 Common Stock shares.
       
      (b) Percent of Class: 5.086% based on 8,316,308 Common Shares outstanding, as reported on Form 10-Q, Quarterly Report Pursuant To Section 13 or 15(d) of The Securities Exchange Act of 1934, filed on October 29, 2020.
       
     

    (c) Number of shares as to which the person has

     

    (i)Sole power to vote or direct the vote: 0
       
    (ii)Shared power to vote or direct the vote: 423,000
       
    (iii)Sole power to dispose or direct the disposition: 0
       
    (iv)Shared power to dispose or direct the disposition: 423,000

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     7 of 9

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐
       
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
       
      None.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      None.
       
    Item 8. Identification and Classification of Members of the Group.
       
      None.
       
    Item 9. Notice of Dissolution of Group.
       
      None.
       
    Item 10. Certifications.
       
      None.

     

    By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     8 of 9

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021

     

      AZ FUND 1 AZ ALLOCATION - TREND
       
     

    By:

    /s/ Giorgio Medda

      Name:  Giorgio Medda
      Title: General Manager, Azimut Investments S.A.
         
     

    AZIMUT INVESTMENTS S.A.

       
     

    By:

    /s/ Giorgio Medda

      Name: Giorgio Medda
      Title: General Manager, Azimut Investments S.A.

     

     

     

     

    CUSIP No. 282644301   SCHEDULE 13G   Page     9 of 9

     

    EXHIBIT 1

     

    JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)

     

    The undersigned hereby agree, on this 12th day of February, 2021, that this Schedule 13G (as so amended, the “Schedule 13G”) with respect to the Common Stock of EKSO Bionics Holdings, Inc. is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other, except to the extent that it knows or has reason to believe that such information is inaccurate.

     


    Dated: February 12, 2021

     

      AZ FUND 1 AZ ALLOCATION - TREND
       
     

    By:

    /s/ Giorgio Medda

      Name:  Giorgio Medda
      Title: General Manager, Azimut Investments S.A.
         
     

    AZIMUT INVESTMENTS S.A.

       
     

    By:

    /s/ Giorgio Medda

      Name: Giorgio Medda
      Title: General Manager, Azimut Investments S.A.

     

     

     

     

     

    Get the next $EKSO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EKSO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $EKSO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Financials

    Live finance-specific insights

    See more
    • Ekso Bionics Reports First Quarter 2025 Financial Results

      SAN RAFAEL, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three months ended March 31, 2025. Recent Highlights and Accomplishments Strengthened financial position by improving operating cash burn by 43% combined with $3.8 million in net proceeds from the exercise of warrantsNamed National Seating & Mobility ("NSM") as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology ("CRT") industryNamed Bionic Prosthetics & Orthotics Group ("Bionic P&O") as its

      5/5/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics to Report First Quarter 2025 Financial Results on May 5 – Conference Call to Follow

      SAN RAFAEL, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the first quarter of 2025 after the close of trading on Monday, May 5, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments. To participate in the conference call by telephone, please dial 877-407-6184 (domestic) or 201-389-0877 (international). The call will also be broadcast live and archived on the Company's website at www.

      4/28/25 4:30:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Reports Fourth Quarter and Full-Year 2024 Financial Results

      SAN RAFAEL, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2024. Recent Highlights and Accomplishments Record Q4-2024 revenue of $5.1 millionQ4-2024 gross margin increased 400 basis points year-over-year to 53%Subsequent to year-end, Company named National Seating & Mobility as its exclusive Ekso Indego® Personal device distributor within the U.S. complex rehabilitation technology (CRT) industry "We are pleased to close out 2024 with recor

      3/3/25 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Leadership Updates

    Live Leadership Updates

    See more
    • Ekso Bionics Accepted into NVIDIA Connect Program

      Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation Collaboration represents an important step toward integrating powerful new AI capabilities into Ekso Bionics' proprietary exoskeleton technology platforms SAN RAFAEL, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) ("Ekso Bionics" or the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced its acceptance into the NVIDIA Connect program. The Company plans to use the valuable tools and resources provided through this prestigious NVIDIA program to support a new strategic

      5/15/25 7:45:00 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Appoints Deborah Lafer Scher to its Board of Directors

      Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso's Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the appointment of Deborah Lafer Scher to its Board of Directors, effective June 6, 2024. "We are pleased to strengthen our Board with the addition of Deborah Lafer Scher, a distinguished leader who brings a wealth of healthcare experience and a proven track record of business development expertise," said Scott Davis, President and Chie

      6/17/24 4:05:00 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Announces Acquisition of Human Motion and Control Business Unit Including Indego® Product Line From Parker Hannifin Corporation

      Broadens Ekso Bionics' product portfolio into home use Adds Vanderbilt University as a key commercial and research partner Acquisition consolidates leading lower extremity robotic companies Ekso President and COO Scott Davis promoted to Chief Executive Officer; Steven Sherman to remain Chairman, appointed Executive Chair SAN RAFAEL, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Ekso Bionics (NASDAQ:EKSO) (the "Company"), an industry leader in exoskeleton technology for medical and industrial use, today announced the acquisition of the Human Motion and Control ("HMC") Business Unit from Parker Hannifin Corporation ("Parker"), a global leader in motion and control technologies. The acquisiti

      12/5/22 8:37:01 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Lathan Corinna bought $15,477 worth of shares (13,733 units at $1.13), increasing direct ownership by 10% to 147,990 units (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/14/24 6:41:52 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ekso Bionics Holdings Inc.

      10-Q - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:08:10 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Ekso Bionics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      5/5/25 4:06:47 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form 11-K filed by Ekso Bionics Holdings Inc.

      11-K - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

      4/18/25 4:25:35 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      11/14/24 3:29:01 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed by Ekso Bionics Holdings Inc. (Amendment)

      SC 13G/A - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/11/22 6:17:59 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G filed

      SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

      2/12/21 10:16:25 AM ET
      $EKSO
      Industrial Machinery/Components
      Industrials

    $EKSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Wong Jerome was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:07:04 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • Chief Operating Officer Jones Jason C was granted 24,248 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:43 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials
    • CEO Davis Scott G. was granted 5,590 shares (SEC Form 4)

      4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

      3/18/25 6:06:18 PM ET
      $EKSO
      Industrial Machinery/Components
      Industrials